In particular, the complaint alleges that throughout the Class Period, defendants made materially false and / or misleading statements and / or failed to disclose that (1) the
trials for GED - 0301 suffered from fatal design defects, such that GED - 0301 had failed to demonstrate meaningful
clinical efficacy; (2) the growth of Otezla sales had dramatically slowed
during Celgene's third fiscal quarter of 2017; and (3) the
clinical and nonclinical pharmacology data in Celgene's new drug application («NDA») for Ozanimod were insufficient to permit a complete review by the FDA, which resulted in the FDA issuing a refusal to file letter to Celgene regarding the NDA.
Many factors may cause differences between current expectations and actual results including unexpected safety or
efficacy data observed
during preclinical or
clinical studies,
clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of Syndax's collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes.